Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Patient-profiled treatment responses in a large hypertension trial: a posthoc analysis of the INSIGHT study.

Journal of hypertension·2026
Same author

Resistant Hypertension Is Not Essential: It Is Primarily Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

EndoCompass Project: Research Roadmap for Adrenal and Cardiovascular Endocrinology.

Hormone research in paediatrics·2025
Same author

Adrenal Aldosterone Synthase Expression Imaging in Primary Aldosteronism.

The New England journal of medicine·2025
Same author

Voxel-Level Comparison of [<sup>18</sup>F]CETO and [<sup>11</sup>C]MTO for Molecular Imaging of Primary Aldosteronism.

Journal of nuclear medicine technology·2025
Same author

EndoCompass project: research roadmap for adrenal and cardiovascular endocrinology.

European journal of endocrinology·2025
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
関連記事をすべて見る

関連する実験動画

Updated: May 11, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

アリスキレン (Aliskiren) とは

Morris J Brown1

  • 1University of Cambridge, Cambridge, UK. m.j.brown@cai.cam.ac.uk

Circulation
|August 13, 2008
PubMed
まとめ
この要約は機械生成です。

経口レニン阻害剤であるアリスキレンは,承認された用量で副作用を最小限に抑え,血圧を効果的に低下させます. モノセラピーまたは組み合わせとして有望であり,特に抵抗性高血圧に対して有望である.

さらに関連する動画

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

関連する実験動画

Last Updated: May 11, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

科学分野:

  • 心血管薬理学について
  • 腎臓系生理学 腎臓系生理学

背景:

  • 高血圧管理は,さまざまな薬剤クラスに依存しています.
  • レニン・アンジオテンシン・アルドステロン系 (RAAS) は,血圧の重要な調節因子である.
  • ターゲティングレニンは,RAAS抑制への直接的なアプローチを提供します.

研究 の 目的:

  • 直接レニン阻害剤であるアリスキレンの有効性と安全性を評価する.
  • 高血圧に対する単独療法および併用療法におけるアリスキレンの役割を評価する.
  • 臨床実務におけるアリスキレンの利用のための最適な戦略を探求する.

主な方法:

  • 血圧低下を評価する臨床試験.
  • 150mgと300mgでの用量反応の評価.
  • 他の抗高血圧薬クラスとの比較分析.
  • 安全性および耐受性の評価とプラセボとの比較.

主要な成果:

  • アリスキレンは,既定の抗高血圧薬と比較できる,用量依存の血圧低下を示した.
  • 副作用はプラセボと同様のものでした.
  • モノセラピーとコンビネーションで有効です.
  • ナトリウレティック剤と併用するとより大きな効果が観察されましたが,二重レニン阻害も効果を示しました.

結論:

  • アリスキレンは,安全で効果的な経口抗高血圧剤です.
  • 制御不能または不耐性高血圧の患者に貴重な選択肢を提供します.
  • レニン系を理解することで,アリスキレンの治療効果を最適化することができます.
  • 血圧以外の心血管疾患の利点を特定するために,さらなるアウトカム研究が必要である.